Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MYGN vs XOMA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XOMA Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 9–1 Matrix Metrics)

XOMA Overall Winner 6-Pillar Tally: MYGN 3 – 3 XOMA Matrix Metrics: MYGN 1 – 9 XOMA

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MYGN carries a Unified Composite Score of 45.9/100 (HOLD) at $5.62 (54.0x Forward P/E, -13.3% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin).

  • Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. MYGN 45.9/100 HOLD) and 0.68β · 37% Vol risk profile, whereas MYGN leads top-line expansion (-1.5% YoY revenue growth, 1.40x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MYGN vs XOMA
MYGN NASDAQ
Myriad Genetics Inc
In Vitro & In Vivo Diagnostic Substances
$5.62
-0.8% 1D
Market Cap $544.8M
TTM Revenue $804M
Forward P/E 54.0x
Beta / 30D Vol 0.69β · 122% Vol
Unified Composite Score
45.9 / 100 HOLD
Tech 30.0 Fund 41.0 Flow 56.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (30.2% over 20 days), RSI 52
RSI-14: 52.0 · SMA20: $5.94 · SMA50: $4.80
XOMA NASDAQ Head-to-Head Winner
XOMA Royalty Corporation Common Stock
Pharmaceutical Preparations
$40.17
-9.16% 1D
Market Cap $781.8M
TTM Revenue $49M
Forward P/E 21.5x
Beta / 30D Vol 0.68β · 37% Vol
Unified Composite Score
55.8 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 35
RSI-14: 34.5 · SMA20: $42.59 · SMA50: $42.06

6-Pillar Scorecard Institutional Category Breakdown (MYGN 3 – 3 XOMA)

Columns: Metric · MYGN · XOMA
1. Valuation Multiples XOMA
Forward P/E 54.0x 21.5x
Trailing P/E 54.0x 28.2x
PEG Ratio 1.40x N/M
EV / Revenue 0.8x 16.1x
2. Growth & Scale MYGN
Revenue Growth (YoY) -1.5% -22.6%
Earnings Growth (YoY) +0.0% +207.9%
TTM Revenue (USD) $804M $49M
Market Cap $544.8M $781.8M
3. Profitability & Quality XOMA
Gross Margin 68.3% 99.0%
Operating Margin -13.3% -3.9%
Net Profit Margin -16.1% 69.6%
Return on Equity (ROE) -40.2% 34.2%
4. Balance Sheet & Cash Flow XOMA
Cash Generation (TTM) -$38M $8.3M EBITDA
Cash Flow Margin -4.7% 17.1% EBITDA Mgn
Net Cash / Leverage $102M Net Debt (0.78x D/E) $7.79 Book/Sh · 34.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MYGN
Options Structure Phase SURGE UNCLASSIFIED
Current IV / %ile 124.6% (22nd %ile) 101.5% (100th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase DISTRIBUTION · Markup NEUTRAL · Neutral
6. R&D & Supply-Chain Moat MYGN
OpEx & R&D Intensity 81.6% of Rev ($656M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Diagnostics & Research Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MYGN (1) vs XOMA (9)
Institutional Metric MYGN XOMA Criterion Row Edge
Market Capitalization
Scale
$544.8M $781.8M Larger Scale XOMA
Trailing P/E Ratio
Valuation
54.0x 28.2x Lower Multiple XOMA
Forward P/E Ratio
Valuation
54.0x 21.5x Lower Multiple XOMA
Revenue Growth (YoY)
Growth
-1.5% -22.6% Higher Growth MYGN
Operating Margin (TTM)
Profitability
-13.3% -3.9% Higher Margin XOMA
Net Profit Margin
Profitability
-16.1% 69.6% Higher Margin XOMA
Return on Equity (ROE)
Capital Efficiency
-40.2% 34.2% Higher ROE XOMA
52-Week Range Position
Momentum
54% ($3–$8) 78% ($22–$45) Stronger Trend XOMA
Beta / 30D Volatility
Risk Regime
0.69β · 122% Vol 0.68β · 37% Vol Lower Realized Risk XOMA
Unified Institutional Score
Composite Signal
45.9 / 100 (HOLD) 55.8 / 100 (HOLD) Higher Composite XOMA
Trailing 12M Revenue (USD)
Operating Scale
$804M $49M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
68.3% 99.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.40x PEG · 0.8x EV/Rev N/M PEG · 16.1x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$38M ($102M Net Debt (0.78x D/E)) $8.3M EBITDA ($7.79 Book/Sh · 34.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MYGN +36.09 pp
MYGN: +32.28% · XOMA: -3.81%
3M Horizon MYGN +25.37 pp
MYGN: +34.71% · XOMA: +9.34%
6M Horizon XOMA +44.93 pp
MYGN: -10.67% · XOMA: +34.26%
1Y Horizon XOMA +32.32 pp
MYGN: -7.72% · XOMA: +24.6%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MYGN vs XOMA. Trailing 12-month operating profitability (MYGN -13.3% vs XOMA -3.9%) and valuation multiples (MYGN 54.0x vs XOMA 21.5x Forward P/E) are benchmarked directly in Pillar 4 below.

MYGN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$804M
Gross Margin68.3%
Op. Margin-13.3%
ROE / Fwd P/E-40.2% · 54.0x
XOMA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$49M
Gross Margin99.0%
Op. Margin-3.9%
ROE / Fwd P/E34.2% · 21.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MYGN SURGE
12d in phase · OBV DISTRIBUTION
Current IV 124.6%
IV Percentile 22nd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact MYGN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XOMA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 101.5%
IV Percentile 100th %ile
Put/Call OI Skew N/A
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact XOMA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MYGN Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $544.8M market capitalization and -13.3% operating margin.
OpEx & R&D Reinvestment 81.6% of Rev ($656M)
90D Engineering Disclosures 0 Published
XOMA Moat Profile Scale & Operating Efficiency Moat
Biotechnology Operator
Competes within the Biotechnology value chain with $781.8M market capitalization and -3.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MYGN vs XOMA Key Questions & Quantitative Answers

As of Nov 16, 2026, XOMA Royalty Corporation (XOMA) is the stronger overall head-to-head candidate over Myriad Genetics Inc (MYGN) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). MYGN carries a Unified Composite Score of 45.9/100 (HOLD) at $5.62 (54.0x Forward P/E, -13.3% operating margin), whereas XOMA carries 55.8/100 (HOLD) at $40.17 (21.5x Forward P/E, -3.9% operating margin). Growth vs. Quality Trade-Off: XOMA earns the overall head-to-head edge with a stronger Unified Composite Score (55.8/100 HOLD vs. MYGN 45.9/100 HOLD) and 0.68β · 37% Vol risk profile, whereas MYGN leads top-line expansion (-1.5% YoY revenue growth, 1.40x PEG, and 3 of 6 institutional pillars) for higher-beta growth mandates.

MYGN leads the Growth & Scale pillar: MYGN posts -1.5% YoY revenue growth and +0.0% YoY earnings growth on $804M TTM revenue (68.3% gross margin, -13.3% operating margin), compared with XOMA at -22.6% YoY revenue growth and +207.9% YoY earnings growth on $49M TTM revenue (99.0% gross margin, -3.9% operating margin). On trailing 12-month operating scale, MYGN generates $804M in USD-normalized revenue versus $49M for XOMA. In operating R&D and SG&A reinvestment, MYGN deploys 81.6% of Rev ($656M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for XOMA.

XOMA screens cheaper on headline valuation multiples. MYGN trades at 54.0x Forward P/E, 54.0x Trailing P/E, 1.40x PEG, and 0.8x EV/Revenue (-4.7% FCF margin), whereas XOMA trades at 21.5x Forward P/E, 28.2x Trailing P/E, N/M PEG, and 16.1x EV/Revenue (17.1% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MYGN (-40.2% ROE) versus XOMA (34.2% ROE) capital efficiency.

In options market volatility and institutional positioning, MYGN carries 124.6% implied volatility (22nd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a SURGE options structure phase (0.69β · 122% Vol realized risk). By comparison, XOMA carries 101.5% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 37% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.